Cancer Therapies Approved by the FDA in December 2024
The FDA approved several drugs in December for the treatment of diseases, including pancreatic adenocarcinoma, lung cancer, skin cancer and graft-versus-host disease.
Related Articles
Over a third of practice nurses spend one hour or less on training a week
More than a third (36%) of general practice nursing staff say they spend one hour or less per week on training and development opportunities
Top Lung Cancer Stories in 2024
CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.
NHS Wales plans to digitise maternity records by next spring | Nursing Times
Read about the upcoming digitisation of maternity patient records and the launch of a new app for expectant mothers in Wales.
NMC appoints second adviser to help with FtP improvements | Nursing Times
Read about the appointment of Professor Donna O’Boyle to the Nursing and Midwifery Council as a seconded executive adviser.
Qualitative study with postnatal women in Turkey provides perspectives on the practice of postnatal debriefing as a desired practice that promotes processing of birth experiences and provides benefits for health and well-being
Commentary on: Demerci AD, Oruc M, Kabukcuoglu K. “I need to make sense of my birth experience”: A descriptive qualitative study of postnatal women’s opinions,…
Scottish nurses ‘desperately struggling’ amid winter pressures | Nursing Times
Read about the nursing response to data showing the number of people admitted to hospital with flu in Scotland has increased.
RCN chief ‘absolutely committed’ to improving pay for all nurses
The RCN chief has renewed her commitment to improving pay for all nursing staff across the UK in a New Year message to the profession.
Survivor’s Guilt: Asking, ‘Why Me?’
Despite being declared cancer-free after initial treatment, I grapple with survivor’s guilt, questioning why my lymphoma responded to therapy while others did not.
FDA Accepts NDA for Avutometinib Plus Defactinib in KRAS+ Low-Grade Serous Ovarian Cancer
An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.
A Nomogram for Predicting Suicide Risk and Prognostic Factors in Bladder Cancer Patients Following Diagnosis: More Information Needed
Click on the article title to read more.
